Local injection of micro‐dose guselkumab for palmoplantar pustulosis after partial failure of systemic ixekizumab treatment

We present a palmoplantar pustulosis case partially resistant to systemic IL‐17A inhibitor (ixekizumab) treatment, and then receiving a local injection of 0.1 mL micro‐dose (1 mg) IL‐23 inhibitor (guselkumab) every 4 weeks for four times. The paradoxical lesion disappeared rapidly following local in...

Full description

Saved in:
Bibliographic Details
Published in:Australasian journal of dermatology 2024-05, Vol.65 (3), p.e75-e76
Main Authors: Zhou, Chaojing, Chen, Dandan, Diao, Ziyue, Wang, Yufei, Hou, Yiyun, Yin, ZhiQiang
Format: Article
Language:English
Subjects:
Antibodies, Monoclonal, Humanized - administration & dosage
Antibodies, Monoclonal, Humanized - adverse effects
Antibodies, Monoclonal, Humanized - therapeutic use
biologics
Dermatologic Agents - administration & dosage
Dermatologic Agents - adverse effects
Dermatologic Agents - therapeutic use
Female
Humans
Injection
Male
Middle Aged
palmoplantar pustulosis
paradoxical reaction
psoriasis
Psoriasis - drug therapy
Pustulosis
therapy
Treatment Failure
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We present a palmoplantar pustulosis case partially resistant to systemic IL‐17A inhibitor (ixekizumab) treatment, and then receiving a local injection of 0.1 mL micro‐dose (1 mg) IL‐23 inhibitor (guselkumab) every 4 weeks for four times. The paradoxical lesion disappeared rapidly following local injection and there was no recurrence after 8 weeks of drug withdrawal. This is the first clinical report on the treatment of palmoplantar pustulosis by local injection of micro‐dose guselkumab.
ISSN:0004-8380
1440-0960
DOI:10.1111/ajd.14244